Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK and MELBOURNE, Australia, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced that results have been presented showing that use of its proprietary...
-
BARCELONA, SPAIN--(Marketwired - Feb 22, 2016) - MOBILE WORLD CONGRESS - Vasona Networks, Inc.®, a provider of platforms for better mobile user experiences, capacity and resource utilization,...
-
BARCELONA, SPAIN--(Marketwired - Feb 22, 2016) - Cisco (NASDAQ: CSCO) -- Deutsche Telekom is creating a multi-country mobile cloud. SK Telecom of South Korea is automating new service creation in...
-
BARCELONA, Spain, Feb. 22, 2016 (GLOBE NEWSWIRE) -- MOBILE WORLD CONGRESS -- Imagination Technologies (IMG.L) announces a new family of mass market PowerVR GPUs that set a new standard...
-
Poster Presentation to Highlight Anti-Tumor Properties of Ex Vivo Programmed Donor T Cells Phase 1/2 Clinical Trial of ProTmune in Mobilized Peripheral Blood HCT to Commence Enrollment in Mid-2016 ...
-
Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting Despite Trial Not Meeting Primary Endpoint Company to Host Conference Call on February 22 at 8:00 a.m. EST to Provide...
-
HAMPTON, N.J., Feb. 20, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented new clinical data on CDX-301 (recombinant human Flt3 ligand), a potent hematopoietic...
-
Mifflintown, PA, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Marcie A. Barber, President and Chief Executive Officer of Juniata Valley Financial Corp. (OTC Pink: JUVF) (“Juniata”), announced that Juniata’s...
-
ARLINGTON, Va., Feb. 19, 2016 (GLOBE NEWSWIRE) -- FBR & Co. (Nasdaq:FBRC) ("FBR" or the “Company”), a leading investment bank serving the middle market, today announced that Tina Pappas has...
-
Reduced length of ICU stay by 3.5 days, hospital stay by 2.5 days versus standard of careBuilds on efficacy data from Phase 1/2 clinical study, where EG-1962 doubled chances of favorable clinical...